Allogene Therapeutics announced that pre‑clinical data for its dual‑targeted CD19/CD70 allogeneic CAR‑T product, ALLO‑329, has been published in the peer‑reviewed journal Nature Communications. The study demonstrates that ALLO‑329 can precisely target both CD19+ B cells and CD70+ activated T cells, key drivers in several autoimmune diseases, and shows robust CAR‑T expansion and persistence in pre‑clinical models.
The publication highlights the company’s Dagger technology, a proprietary platform designed to reduce or eliminate the need for intensive lymphodepletion. By enabling a lower‑dose, lymphodepletion‑sparing therapy, the technology could allow outpatient administration and improve safety for patients with systemic lupus erythematosus, scleroderma, and inflammatory myositis. The data provide independent validation of the platform’s safety and efficacy profile in autoimmune disease, a large and underserved market.
Allogene is currently enrolling patients in the Phase 1 RESOLUTION trial, which is testing ALLO‑329 in individuals with systemic lupus erythematosus, scleroderma, and inflammatory myositis. Initial data from the first dosing cohort are expected in June 2026, and the trial’s outcomes will be critical for advancing the product toward regulatory approval.
Earlier this week, the company announced a $175 million underwritten public offering of common stock priced at $2.00 per share. The equity raise is a significant financing event that dilutes existing shareholders but strengthens the balance sheet and extends the company’s cash runway into the first quarter of 2028. Allogene’s annual cash burn is approximately $150 million, and the company had $258.3 million in cash and cash equivalents as of December 31 2025.
"The preclinical data published in Nature Communications highlight the potential of ALLO‑329's dual‑targeting approach to address both B‑ and T‑cell drivers of autoimmune disease," said Zachary Roberts, M.D., Ph.D., EVP of Research and Development and Chief Medical Officer. "By combining precision targeting with an off‑the‑shelf platform, we believe ALLO‑329 has the potential to deliver a more complete and scalable treatment approach without the need for intensive lymphodepletion. We are excited to advance this program and explore its potential across a range of autoimmune diseases."
The equity raise and the publication of pre‑clinical data together underscore Allogene’s dual focus on advancing a promising therapeutic platform while securing the financial resources needed to support its clinical development program. The company remains a clinical‑stage biotechnology firm with no revenue yet, but the recent financing and scientific milestone position it to pursue further clinical studies and potential regulatory submissions in the coming months.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.